Allergy, Asthma, and Atopic Eczema in Finland

Study acronym: FinnATOPY
StatusNot Yet Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 40% 2000000 → 1200000 participants
See other at-risk trials from Tampere University

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment reduced: 2000000 → 1200000 participants Show 5 more changesShow less
    • Start date: Oct 2024 to Dec 1, 2026
    • Interventions modified
    • Trial arms changed: 0 → 6
    • Eligibility criteria revised
    • Study description revised
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Tampere University
17 trials monitored
See 1 trial at risk
Asthma
958 trials monitored
See 36 trials at risk
Atopic Dermatitis
500 trials monitored
See 18 trials at risk
The summary is available at --\> https://www.finnatopy.fi/summary
Trial Details
NCT Number NCT06330974
Lead Sponsor Tampere University
Collaborators: Professor Lauri Lehtimäki, Professor Mika Mäkelä, Professor Sanna Toppila-Salmi, Professor Ilkka Junttila
Conditions
(from sponsor)		 Asthma, Asthma in Children, Allergy, Rhinitis, Allergic, Atopic Dermatitis, Allergen Immunotherapy
Related terms Asthma, Dermatitis, Atopic, Hypersensitivity, Rhinitis, Allergic
Enrollment 1,200,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov